跳至主要内容
临床试验/NCT04263025
NCT04263025进行中(未招募)2 期

Prospective, Controlled Study Evaluating Recovery of Potency and Continence Following Robot-Assisted Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

Hackensack Meridian Health1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2020年1月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
进行中(未招募)
入组人数
100
试验地点
1
主要终点
Erectile function

研究概览

简要总结

This study aims at evaluating if placement of CLARIX® CORD 1K during robotic prostatectomy decreases the time to achieve complete erectile and urinary function after the surgery. As part of the study, the patient will be asked to answer various questions after the surgery regarding sexual and urinary function.

详细描述

One hundred male patients who are scheduled for bilateral, nerve-sparing RARP that meet the eligibility criteria will be enrolled. These patients will be equally randomized (1:1) into two groups (n=50/group): one group will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during RARP, while the other group will undergo RARP without adjunctive CLARIX® CORD 1K. Subject stratification will be performed based on the surgeon that will be performing the RARP. All patients will be given the same routine preoperative, perioperative and postoperative evaluation and care aside from the CLARIX CORD 1K placement in the treatment group during RARP. RARP will be performed at Hackensack University Medical Center (30 Prospect Ave, Hackensack, NJ 07601) and follow up visits performed at Hackensack University Medical Group Urology (360 Essex Street, Suite 403, Hackensack, NJ 07601) or New Jersey Urology (255 W. Spring Valley Avenue Suite 101, Maywood, NJ 07607).

Two weeks prior to the RARP surgery, subjects are instructed to take low-dose oral phosphodiesterase type 5 inhibitors (i.e. 20 mg q.d. sildenafil citrate or 5 mg q.d. tadalafil) and perform standardized Kegel exercises (3x/day) which is our current standard care protocol. RARP surgery will be performed at Hackensack University Medical Center (Hackensack, NJ). The following are the key aspects of the RARP surgical technique which will be adhered to by all surgeons: 1) dissection of the bladder neck, seminal vesicles and vasa deferentia; 2) dissection of the neuroplexus from the posterior Denonvilliers' fascia and lateral prostatic fascia leaving the nerves intact; 3) division of the prostatic pedicles without cautery; 4) transection of the dorsal venous complex; and 5) urethrovesical anastomosis. More specifically, surgical technique includes exposing the prostate in the space of Retzius with the traditional anterior approach.

The prostatovesical tissue is dissected with monopolar electrocautery scissors with entry into the bladder proximal to the prostatovesical junction. The bladder neck is transected in the standard fashion followed by posterior dissection of the seminal vesicles and vasa deferentia.

Electrocautery is kept to a minimum when dissecting the seminal vesicles to avoid damage to the neuroplexus. (Note: each step hereafter must be performed by the PI or Sub-investigators, e.g. not a Resident Physician). A posterior surgical plane is then created between the rectum and prostate dorsally working from a medial to lateral direction and maintaining at least 1 layer of Denonvilliers' fascia on the rectal wall. The endopelvic fascia is then excised from lateral prostate and carried to capsule to create a plane of dissection immediately alongside the prostatic capsule and keeping the nerves attached laterally to the endopelvic fascia. Athermal division of each prostatic pedicle will be performed. Clips or suture may be placed on each pedicle at the discretion of the surgeon. The apex of the prostate is then dissected athermally sparing the neuroplexus. The dorsal vein complex is proximally transected with electrocautery while using the fourth arm to place traction on the prostate to define the space between the dorsal vein complex and the apex of the prostate. Apically, the prostate is divided from the urethra (paying special attention to the sphincter muscle and posterior lateral nerve bundle on each side) allowing the prostate to be removed. Once free, the prostate is placed in a collection bag and a drain is used for a certain period at the discretion of the surgeon.

Surgical site bleeding is managed using standard surgical techniques with sutures or cellulose polymer. If the patient is randomized to the treatment group, CLARIX CORD 1K is placed flat over the neuroplexis at the 5 and 7 clock position where the largest concentration of nerves exist. Sutures may be used to secure the CLARIX in place if necessary and cellulose polymer (Surgicel, Ethicon, Somerville, NJ) can be placed over the CLARIX CORD at the discretion of the physician.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

Participant will be Blinded

入排标准

年龄范围
30 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者
否

入选标准

  • •Male aged between 30 and 70 years old
  • •Primary diagnosis of organ confined prostate cancer
  • •Scheduled to undergo bilateral, nerve-sparing RARP
  • •Patient has ICIQ-SF score <6
  • •Patient has no erectile dysfunction (defined as IIEF-6 score ≥ 26)
  • •Patient is willing to return for all visits as defined in the protocol
  • •Patient is willing to follow the instruction of the Investigator
  • •Patient has provided written informed consent

排除标准

  • •Previous history of pelvic radiation
  • •Previous history of simple prostatectomy or transurethral prostate surgery
  • •Previous history of systemic therapy for prostate cancer
  • •Patient has neurogenic bladder
  • •Body weight less than 50 kg (110 pounds) or a body mass index greater than 40 kg/m2
  • •History of open pelvic surgery within 5 years except for hernia repair
  • •Scheduled at the time of screening to undergo chemotherapy, radiation, hormone therapy, or open surgery during the study period.
  • •Any neurologic disorder or psychiatric disorder (e.g., Parkinson's Multiple Sclerosis, etc.) that might confound postsurgical assessments
  • •Received administration of an investigational drug within 30 days prior to study, and/or has planned administration of another investigational product or procedure during participation in this study
  • •Previous history of anaphylaxis or hypersensitivity to liposomal amphotericin- B

研究组 & 干预措施

CLARIX CORD 1K

Experimental

They will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during Robot-Assisted Radical Prostatectomy (RARP).

干预措施: Cryopreserved Umbilical Cord Allograft (Biological)

CLARIX CORD 1K

Experimental

They will receive adjunctive CLARIX® CORD 1K (Amniox Medical, Inc., Miami, FL) during Robot-Assisted Radical Prostatectomy (RARP).

干预措施: Robot-Assisted Radical Prostatectomy (Procedure)

Controls

Active Comparator

They will undergo RARP without adjunctive CLARIX® CORD 1K.

干预措施: Robot-Assisted Radical Prostatectomy (Procedure)

结局指标

主要结局

Erectile function

时间窗: At twelve months post surgery

Erectile function will be evaluated using the International Index of Erectile Function (IIEF)

Erectile function

时间窗: At three months post surgery

Erectile function will be evaluated using the International Index of Erectile Function (IIEF)

Erectile function

时间窗: At six months post surgery

Erectile function will be evaluated using the International Index of Erectile Function (IIEF)

次要结局

  • Failure Events of Following RARP endpoint(2 weeks post-op)
  • Potency endpoint(12 months post op)
  • Return to continence(At twelve months post surgery)
  • Sexual encounter(At twelve months post surgery)
  • Biochemical recurrence endpoint(12 months post-op)
  • Patient intercourse satisfaction endpoint(12 months post op)
  • Pad Weight(12 months post op)
  • Pad Count(12 months post op)
  • Potency endpoint(6 weeks post op)
  • Potency endpoint(3 months post op)
  • Potency endpoint(6 months post op)
  • Return to continence(At 6 weeks post surgery)
  • Return to continence(At three months post surgery)
  • Return to continence(At six months post surgery)
  • Pad Weight(6 weeks post op)
  • Pad Count(6 weeks post op)
  • Pad Weight(3 months post op)
  • Pad Count(3 months post op)
  • Pad Weight(6 months post op)
  • Pad Count(6 months post op)
  • Sexual encounter(At three months post surgery)
  • Sexual encounter(At six months post surgery)
  • Biochemical recurrence endpoint(6 weeks post-op)
  • Biochemical recurrence endpoint(3 months post-op)
  • Biochemical recurrence endpoint(6 months post-op)
  • Patient intercourse satisfaction endpoint(6 weeks post op)
  • Patient intercourse satisfaction endpoint(3 months post op)
  • Patient intercourse satisfaction endpoint(6 months post op)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验